Insurance coverage and the treatment of mental illness: Effect on medication and provider use

Journal of Mental Health Policy and Economics

Volumn 11, Issue 4, 2008, Pages 177-199

  Mulvale, Gillian ^a,b   Hurley, Jeremiah ^b  

^a Mental Health Commission of Canada   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ARTICLE; CANADA; COMMUNITY CARE; DEMOGRAPHY; DRUG UTILIZATION; GENERAL PRACTITIONER; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; MENTAL DISEASE; MENTAL HEALTH SERVICE; PRESCRIPTION; PSYCHIATRIST; PSYCHOLOGIST; SOCIAL WORKER; SOCIOECONOMICS;

AGE FACTORS; ANTIPSYCHOTIC AGENTS; CANADA; COMMUNITY HEALTH SERVICES; DRUG UTILIZATION; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MENTAL DISORDERS; MENTAL HEALTH; MENTAL HEALTH SERVICES; SEX FACTORS; SOCIOECONOMIC FACTORS;

EID: 58149501154     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Dewa C, Hoch J, Steele L. Prescription drug benefits and Canada's uninsured. Int J Law Psychiatry 2005; 28: 496-513.
2. The Daily: Canadian Community Health Survey: Mental health and well-being. Accessed on April 26, 2006, http://www.statcan.ca/Daily/ English/030903/d030903a.html.
3. Beck C, Williams J, Wang J, Kassam A, El-Guebaly N, Currie S, Maxwell C, Pattenal S, Psychotropic medication use in Canada. Can J Psychiatry 2005; 50(10): 605-613.
4. Vasiliadis H, Lesage A, Adair C, Boyer R. Service use for mental health reasons: Cross-provincial differences in rates, determinants, and equity of access. Can J Psychiatry 2005; 50 (10): 614-619.
5. Vasiliadis H, Lesage A, Adair C, Wang P, Kessler R. Do Canada and the United States Differ in Prevalence of Depression and Utilization of Services? Psychiatr Serv 2007; 58: 63-71.
6. Gravel R, Beland Y. The Canadian Community Health Survey: Mental health and well being. Can J Psychiatry 2005; 50 (10): 573-579.
7. Streiner D, Psychiatric epidemiology in Canada and the CCHS study. Can J Psychiatry 2005; 50(10): 571-572.
8. Sareen J, Cox B, Afifi T, Clara I, Yu N. Perceived need for mental health treatment in a nationally representative Canadian sample. Can J Psychiatry 2005; 50(10): 643-651.
9. Somers J, Goldner E, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: A systematic review of the literature. Can J Psychiatry 2006; 51(2): 100-113.
10. Starkes J, Poulin C, Kisely S, Unmet need for the treatment of depression in Atlantic Canada. Can J Psychiatry 2005; 50 (10): 580-590.
11. Coombes M, Morgan S, Barer M, Pagliccia N. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs? Longwoods Rev 2004; 2 (3): 13-26.
12. Willison D, Grootendorst P, Hurley J. Variation in pharmacare coverage across Canada. CHEPA WP 9808, Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, ON 1998.
13. Canada Life and Health Insurance Association. Facts and figures by province. Accessed on June 6, 2006, http://www.clhia.ca/e5.html.
14. Canada Life and Health Insurance Association. The role of supplementary health insurance in Canada's health system. Accessed Oct. 4, 2006, http://www.clhia.ca/submissions/2001/Supp_Health_Ins/ SSC.PDF.
15. Service J. Personal Communication. 2004.
16. Buchmueller T, Grumbach K, Kronick R, Kahn J. The effect of health insurance on medical care utilization and implications for insurance expansion: A review of the literature. Med Care Res Rev 2005; 62(1):3-30.
17. Cameron A, Trivedi P, Milne F, Piggott J. A microeconometric model of the demand for health care and health insurance in Australia. Rev Econ Stud 1988; LV: 85-106.
18. Doiron D, Salale V, Savage E. The effect of private health insurance on health care utilization. In Explorations in Health. Copenhagen: IHEA Sixth World Congress, Conference Reports, 2007.
19. Lahiri K, Xing G. An econometric analysis of Veteran's health care utilization using two-part models. Department of Economics, University of Albany, NY 2002.
20. Schokkaert E, Van Ourti T, De Graeve D, Lecluysc A, Van de Voorde C. Supplemental Health Insurance and Equality of Access in Belgium, Center for Economic Studies Discussions Paper Series (DPS) 07.29, Department of Economics, University Leuven, Belgium 2007.
21. Finkelstein A. The effect of tax subsidies to employer-provided supplementary health insurance: Evidence from Canada. J Public Econ 2002; 84 (3): 305-339.
22. Windmeijer F, Santos Silva J. Endogeneity in count data models: An application to demand for health care. J Appl Econometrics 1997; 12: 281-294.
23. Stabile M. Private insurance subsidies and public health care markets: evidence from Canada. Can J Econ 2001; 34(4): 921-942.
24. Wooldridge J. Econometric Analysis of Cross Section and Panel Data Cambridge: MIT Press, 2002.
25. Anis A, Guh D, Lacaille C, Marra C, Rashidi A, Li X, Esdaile J. When patients have to pay a share of drug costs: effects on frequency of phsyician visits, hospital admissions and filling of prescriptions. Can Med Assoc J 2005: 173(11): 1335-1340.
26. Jacobs P, Dewa C, Bland R, Eng K, Ohinmaa A, Yim R, Chuck A, Varney J. Mental Health Economic Statistics in Your Pocket. Edmonton: The Alberta Mental Health Board and Institute for Health Economics, 2006.
27. Addington D, Bouchard R, Goldberg J, Honer B, Malla A, Norman R, Tempier R, Berzins S. Clinical Practice Guidelines Treatment of Schizophrenia. Can J Psychiatry 2005 15 (30): S1.
28. Yatham L, Kennedy S, O'Donovan C, Parikh, S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P, Beaulieu S, Daigneault A, Miley R, Young L, Ravindran A, Schaffer A, Connolly M, Gorman C. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7(S3): 5-69.
29. Loosbrock D, Zhao Z, Johnstone B, Stockwell Morris L. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ 2003; 6: 67-75.
30. Bambauer K, Safran D, Ross-Degnan D, Zhang F, Adams A, Gurwitz J, Pierre-Jacques M, Soumerai S. Depression and Cost-Related Medication Nonadherence in Medicare Beneficiaries. Arch Gen Psychiatry 2007; 64: 602-608.
31. Piette J, Heisler M, Wagner T. Cost-Related Medication Underuse Among Chronically Ill Adults: the Treatments People Forgo, How Often, and Who Is at Risk. Am J Public Health 2004; 94(10): 1782-1787.
32. Tamblyn R, Laprise R, Hanley J, Abrahamowicz M, Scott S, Mayo N, Hurley J, Grad R, Latimer E, Perreault R, McLeod P, Huang A, Larochelle P, Mallet L. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. J Am Med Assoc 2001; 285(4): 421-429.
33. DeLeon P, Wakefield M, Schultz A, Williams J, VandenBos G. Rural America. Unique opportunities for health care delivery and health services research. Am Psychol 1989; 44 (10): 1298-1306.
34. Rhodes A, Lin E, Mustard C. Self-reported use of mental health services versus administrative records: should we care? Int J Methods Psychiatr Res 2002; 11(3): 125-133.
35. KPMG, Tax Facts 2000-2001. Toronto: KPMG, 2000.